nVerses Capital’s Larimar Therapeutics LRMR Stock Holding History

nVerses Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,004	Closed	-$58.5K	–	445
2026 Q1	$58.5K	Buy	+13,004	New	+$52K	0.05%	337

Other funds holding LRMR

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

nVerses Capital's LRMR Position: Q2 2026 in Review

nVerses Capital sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 13,004 shares — an estimated $58.5K sold.

nVerses Capital first reported a position in LRMR in Q1 2026 and held it in 1 quarter. The position peaked at $58.5K in Q1 2026. 104 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

nVerses Capital reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 13,004 Larimar Therapeutics shares in Q2 2026, an estimated $58.5K.
nVerses Capital first reported a position in Larimar Therapeutics in Q1 2026 and held it in 1 quarter.
nVerses Capital's Larimar Therapeutics position peaked at $58.5K in Q1 2026.
104 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.